Form 4 Filing for Fred Aslan

This filing details a transaction by Fred Aslan, Chief Executive Officer and Director of Artiva Biotherapeutics, Inc. (ARTV). On October 5, 2026, Aslan sold 61,696 shares of common stock at a price of $6.8372 per share. This sale was conducted under a "sell-to-cover" policy adopted by the issuer to satisfy tax withholding obligations related to the vesting and release of restricted stock units. The sales were automatic and not at Aslan's discretion. Following this transaction, Aslan owns 1,543,069 shares of common stock.